Aptevo Therapeutics Inc. (APVO) — SEC Filings
Aptevo Therapeutics Inc. (APVO) — 50 SEC filings. Latest: 10-K (Mar 26, 2026). Includes 30 8-K, 6 S-1, 4 10-Q.
View Aptevo Therapeutics Inc. on SEC EDGAR
Overview
Aptevo Therapeutics Inc. (APVO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer, utilizing its proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms. The company's lead clinical candidate, mipletamig, a CD123xCD3 T cell engager, i
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for Aptevo Therapeutics Inc. is neutral.
Filing Type Overview
Aptevo Therapeutics Inc. (APVO) has filed 2 10-K, 30 8-K, 4 10-Q, 6 S-1, 3 DEF 14A, 3 S-1/A, 1 SC 13G/A, 1 SC 13G with the SEC between Aug 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of APVO's 47 recent filings, 4 were flagged as high-risk, 21 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Marvin L. White
- SoYoung Kwon
- Sean M. Donahue
- Charles E. Phillips
Industry Context
Aptevo operates in the highly competitive clinical-stage biotechnology sector, focusing on oncology immunotherapies. The market for cancer treatments is rapidly evolving, with a significant trend towards bispecific antibodies and T cell engagers, as evidenced by the 15 FDA-approved bispecifics, 11 of which are cancer treatments. Companies in this space face intense competition from both large pharmaceutical firms and smaller biotech companies, all vying for market share and investor capital.
Top Tags
sec-filing (10) · regulatory-filing (8) · 8-K (8) · Biotechnology (7) · material-agreement (7) · 8-k (5) · financials (5) · Dilution Risk (5) · filing (4) · pharmaceuticals (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $9.8 million | as of June 30, 2025, indicating a smaller reporting company status |
| Shares of common stock outstanding | 1,181,725 | as of March 26, 2026 |
| Freedom from cytokine release syndrome (CRS) | 100% | observed in 28 evaluable frontline AML patients treated with mipletamig in RAINIER trial |
| Clinical benefit rate | 86% | observed in 28 evaluable frontline AML patients treated with mipletamig in RAINIER trial |
| Complete remission or complete remission with incomplete hematologic recovery (CR/CRi) | 79% | observed in 28 evaluable frontline AML patients treated with mipletamig in RAINIER trial |
| Patients achieving measurable residual disease-negative level | 55% | among those with CR/CRi in frontline AML patients treated with mipletamig |
| Patients with TP53 genetic mutation achieving remission | 35% | in frontline AML patients treated with mipletamig, a high-risk biomarker |
| Patients achieving stable disease | 58% | in ALG.APV-527 dose escalation trial for solid tumors (19 patients) |
| Expected conclusion of RAINIER trial | 2026 | in the second half of the year |
| Bispecifics approved by FDA | 15 | 11 of which are cancer treatments, highlighting market potential |
| SEC File Number | 001-37746 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 81-1567056 | Company's tax identification number. |
| Net Loss | $20.161M | for the nine months ended September 30, 2025, increased from $17.818M in 2024 |
| Accumulated Deficit | $269.2M | as of September 30, 2025, indicating significant historical losses |
| Cash and Cash Equivalents | $21.061M | as of September 30, 2025, up from $8.714M at December 31, 2024 |
Frequently Asked Questions
What are the latest SEC filings for Aptevo Therapeutics Inc. (APVO)?
Aptevo Therapeutics Inc. has 50 recent SEC filings from Aug 2024 to Mar 2026, including 30 8-K, 6 S-1, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APVO filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 43 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Aptevo Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aptevo Therapeutics Inc. (APVO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aptevo Therapeutics Inc.?
Key financial highlights from Aptevo Therapeutics Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for APVO?
The investment thesis for APVO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aptevo Therapeutics Inc.?
Key executives identified across Aptevo Therapeutics Inc.'s filings include Marvin L. White, SoYoung Kwon, Sean M. Donahue, Charles E. Phillips.
What are the main risk factors for Aptevo Therapeutics Inc. stock?
Of APVO's 47 assessed filings, 4 were flagged high-risk, 21 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Aptevo Therapeutics Inc.?
Forward guidance and predictions for Aptevo Therapeutics Inc. are extracted from SEC filings as they are enriched.